Compare AbCellera Biologics Inc (ABCL) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Avantis International Small Cap Value ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Avantis International Small Cap Value ETF trades at $102.95. Which is the better fit depends on your goals.
| ABCL | AVDV | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $8.12 | $110.40 |
52-Week Low | $2.78 | $80.02 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AVDV trades at $105.77, up 1.29% today, with a bullish technical signal from moving averages. The ETF focuses on international small-cap value stocks, delivering strong performance with 35% gains highlighted in recent coverage. Dividend payments provide additional investor returns, with the next $1.39 distribution scheduled for June 2026.
Outlook remains positive given international small-cap value momentum, though cyclical sector exposure and reliance on regional factors present risks. Structural alpha concerns noted by analysts suggest monitoring performance drivers beyond broad market trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
